All Posts

No Pain, No Gain: The Paradigm Story (ASX: PAR)

Jun 22, 2026

•

9 min read

Tax On, Tax Off: What new changes mean for biotech

Jun 19, 2026

•

4 min read

Catalyst Munting: Cynata (CYP) Trial Pulls up Short

Jun 18, 2026

•

4 min read

Fireside Conversation with Emyria

Jun 17, 2026

•

4 min read

Catalyst Hunting: The Actinogen Story (ASX: ACW)

Jun 16, 2026

•

10 min read

The Hardest Sport in Business: Attention

Jun 15, 2026

•

3 min read

A Sweaty Mess: The Botanix Story (ASX: BOT)

Jun 12, 2026

•

8 min read

The Competitive Landscape of the Healthcare World Cup

Jun 11, 2026

•

6 min read

Big Game Hunting: The Imricor Story (ASX: IMR)

Jun 10, 2026

•

11 min read

The Big Freeze: Neale’s legacy lives on

Jun 9, 2026

•

4 min read

Opthea Trade Update: The Final Boss Levelled Up

Jun 5, 2026

•

3 min read

5 Tax Loss Trading Stocks I’m Watching

Jun 4, 2026

•

7 min read

1 2 3 4...12

All Posts

No Pain, No Gain: The Paradigm Story (ASX: PAR)

Tax On, Tax Off: What new changes mean for biotech

Catalyst Munting: Cynata (CYP) Trial Pulls up Short

Fireside Conversation with Emyria

Catalyst Hunting: The Actinogen Story (ASX: ACW)

The Hardest Sport in Business: Attention

A Sweaty Mess: The Botanix Story (ASX: BOT)

The Competitive Landscape of the Healthcare World Cup

Big Game Hunting: The Imricor Story (ASX: IMR)

The Big Freeze: Neale’s legacy lives on

Opthea Trade Update: The Final Boss Levelled Up

5 Tax Loss Trading Stocks I’m Watching

The Armchair Analyst